Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). A Multicenter Single Arm Open Label Phase II Trial.

NCT04472949 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT04472949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04472949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). A Multicenter Single Arm Open Label Phase II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 25, 2021
Completion date
December 31, 2027
Enrollment
46 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, small cell lung cancer